All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Global Portal were delighted to speak to Guy Sauvageau, Maisonneuve-Rosemont Hospital, Montreal, CA, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Guy Sauvageau: Why should we target RUNX1 in AML treatment?
Guy Sauvageau explains targeting RUNX1 in AML treatment. He explains different subsets of genetic mutations confer different treatment response and discusses his work in identifying small molecule compounds that aims to reinstate sensitivity to treatment in a specific subset of AML.
Why should we target RUNX1 in AML treatment?
Your opinion matters
Are there germline RUNX1 mutations which predispose to AML?
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Ravi Majeti, Stanford University, Stanford, US. We asked: Are...
ESH 2019 | Is there a need to change AML risk stratification?
Eytan Stein discusses the current use of risk stratification systems promulgated by the World Health Organization (WHO) and European Leukemia Net (ELN) of stratifying patients into...
Subscribe to get the best content related to AML delivered to your inbox